Abstract
AbstractBackgroundSeveral studies have suggested that the known biomarkers and the diagnostic scales are unreliable for the diagnosis of Kampo‐induced liver injury (KMILI).Diagnostic BiomarkersThe lymphocyte transformation test (LTT) for Kampo medicines is likely to give false positive results, while the normal level of the basophil activation test (BAT) for diagnosing Kampo liver injury remains uncertain.Diagnostic ScaleDue to the lack of reliable biomarkers, diagnostic scales have been developed; however, the Digestive Disease Week [DDW])‐Japan criteria, which is widely used in Japan, has extremely low specificity for diagnosing KMILI.ConclusionThe diagnosis of KMILI remains challenging, and we eagerly await the development of reliable biomarkers for KMILI.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
